Ad Header



The Pulse of the Pharmaceutical Industry

Pfizer posts 30 percent rise in Q2 2019 profit

Written by: | | Dated: Monday, July 29th, 2019


Pfizer posts 30% rise in quarterly profit


(Reuters) – Pfizer Inc (PFE.N) on Monday reported a 30% rise in quarterly profit, helped by demand for its branded treatments such as Ibrance, Eliquis and Xeljanz.

Pfizer, which was scheduled to report its second-quarter earnings on Tuesday, also said it would combine Upjohn, its off-patent drugs business, with Mylan NV (MYL.O).

Pfizer said net income rose to $5.05 billion, or 89 cents per share, in the second quarter, from $3.87 billion, or 65 cents per share, a year earlier.

Revenue fell 1.5% to $13.26 billion.


Reporting by Tamara Mathias in Bengaluru; Editing by Maju Samuel


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom